SEATTLE--(BUSINESS WIRE)--Sep 5, 2018--LabConnect, LLC, a leading global provider of central laboratory and support services for biopharmaceutical, medical device and contract research organizations, today announced that its board of directors has elected Eric I. Richman as chairman of the board.

“I’m delighted Eric has accepted the role of chairman of LabConnect,” said Eric Hayashi, president and CEO. “He brings with him an insider’s knowledge of the needs of our biopharmaceutical clients, and I look forward to a close relationship with him as we write the next chapter of LabConnect’s story together.”

Richman will succeed Alain Chetrit, LabConnect cofounder and chairman, who will now serve as chairman emeritus. During Chetrit’s tenure as board chairman, LabConnect experienced sustained compound annual growth of more than 30 percent.

“I am proud to have had the opportunity to create and contribute to a thriving organization that betters lives, and I’m confident that Eric Richman will help guide the company on a similar trajectory,” said Chetrit.

“Alain, together with Eric and his team, has done a terrific job building a growth engine with a passion for listening and responding to the unique needs of small to midsized biopharmaceutical clients. I’m grateful for Alain’s service over the last 16 years,” added Eric Richman. “I’m excited to take part in transformational innovation in our industry.”

Richman has more than 25 years of experience as a life science executive as a founding team member of MedImmune where he was responsible for the launch of MedImmune’s first commercial product, CytoGam ®, and as president and CEO of PharmAthene. His board experience at biopharmaceutical companies includes ADMA Biologics (NASDAQ: ADMA), NovelStem, Inc., Lev Pharmaceuticals and Tyrogenex.

About LabConnect, LLC Founded in 2002, LabConnect provides global central laboratory and client-inspired support services including routine and specialized laboratory testing, kit building, sample management, data management, biorepository and scientific support services for biopharmaceutical and CRO clients. LabConnect’s unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets and extensive specialized testing expertise means that drug development companies can rely on one provider for their central laboratory and preclinical through Phase IV clinical development needs. Learn more at or connect with LabConnect on LinkedIn.

View source version on

CONTACT: LabConnect, LLC

Jaimy McCarthy, 206-322-4680



SOURCE: LabConnect, LLC

Copyright Business Wire 2018.

PUB: 09/05/2018 08:00 AM/DISC: 09/05/2018 08:01 AM